Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of different combination chemotherapy regimens in treating infants who have newly diagnosed neuroblastoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: European Infant Neuroblastoma Study Group - 1999
• Treatments: Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Liposomal doxorubicin; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed newly diagnosed stage IV or IVS neuroblastoma or ganglioneuroblastoma

• Metastases confined to marrow, skin, nodes, or liver

• No metastases to bone (radiologic bone lesions in skeleton), CNS, pleura, or lung

• No MYCN amplification (i.e., fewer than 10 copies)

PATIENT CHARACTERISTICS:

Age:

• Under 12 months at diagnosis

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified